• Explore /
  • Poster
  • / Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.

Abstract Video & Slides Poster

Authors

Martin Gutierrez

Martin Gutierrez

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

Martin Gutierrez , Vivek Subbiah , John J. Nemunaitis , Niharika B. Mettu , Kyriakos P. Papadopoulos , Minal A. Barve , Luis Féliz , Christine Francis Lihou , Chenwei Tian , Tao Ji , Ian M. Silverman , Rashmi Chugh , Mansoor N. Saleh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02393248

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3606)

DOI

10.1200/JCO.2020.38.15_suppl.3606

Abstract #

3606

Poster Bd #

336

Abstract Disclosures

Similar Posters

First Author: Galam Leem

First Author: Dale Randall Shepard

First Author: Tony S. K. Mok

First Author: Junho Kang